Enveda Raises $311M Series E for Clinical Drug Pipeline

Enveda has reached the point where its AI thesis must survive the expensive half of biotechnology: later-stage clinical development. The Boulder company closed a $311M Series E on September 23, 2026, led by Catalio Capital Management, after reporting early clinical results from two medicines discovered with its PRISM platform.

The financing brings Enveda's company-reported capital raised since inception to more than $845M. It also gives the company a crossover investor base spanning specialist healthcare capital and technology investors as it advances three clinical-stage medicines, adds programs to the clinic, and scales the AI and laboratory infrastructure behind them.

That transition matters because finding an interesting molecule and proving a medicine are different businesses. Enveda has built its identity around making nature's chemistry searchable. The Series E is funding the organization that must now turn that search advantage into repeatable clinical evidence.

What Enveda Announced

Catalio led the Series E and added co-founder and managing partner George Petrocheilos to Enveda's board. New investors include Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, an unnamed sovereign wealth fund, and Alderline Group. Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, and Lux Capital returned.

Enveda plans to use the capital to move ENV-294 and ENV-308 into later-stage trials and additional indications, advance ENV-6946 through mid-phase development, bring more inflammatory and metabolic programs into human testing, and continue scaling PRISM and the automated laboratory that supplies it with experimental data. The round follows Enveda's $150M Series D in September 2025. At that point, the company had entered the clinic with its lead program and described a pipeline stretching from discovery through clinical development. One year later, three Enveda medicines are in human trials, giving the Series E a different job: finance more expensive evidence rather than another platform demonstration.

How PRISM Searches Nature's Chemistry

Enveda was founded in 2019 by CEO Viswa Colluru around the idea that living organisms contain an enormous library of biologically active molecules that conventional discovery methods cannot efficiently identify. The company's PRISM foundation model interprets mass-spectrometry data, predicts molecular structures, guides laboratory experiments, and helps rank molecules by therapeutic potential.

That approach begins with chemistry found in plants, microbes, and the human body rather than designing every molecule from scratch. Enveda's chemists then refine selected starting points into oral candidates with properties suitable for drug development. The company reports that the platform has produced 17 development candidates, including the three now being tested in people.

The operating advantage, if Enveda can sustain it, comes from connecting computation to a physical discovery loop. Models narrow the chemical search. Automated experiments produce new evidence. Medicinal chemistry turns promising signals into candidates. Clinical development then decides whether the entire loop found something useful enough for patients.

Three Clinical Programs Carry the Thesis

ENV-294 is an oral inflammatory-disease candidate being studied in atopic dermatitis and asthma. Enveda reported that eczema severity improved by an average of 85% after 42 days in a Phase 1b study, with no serious side effects reported. Phase 2 studies are underway. Those data are encouraging, but they remain early and company-reported; later trials must establish durability, dosing, comparative value, and a fuller safety profile.

ENV-308 is inspired by Lac-Phe, a molecule released during intense exercise. Enveda is developing the once-daily oral candidate for metabolic health, including the possibility of helping people maintain weight loss after stopping GLP-1 medicines. The first Phase 1 study in 88 healthy volunteers reported favorable safety and tolerability. It was not designed to prove weight-loss maintenance, so the commercial promise still depends on efficacy trials in the target population.

ENV-6946 is an oral candidate for inflammatory bowel disease that targets several inflammatory pathways. It entered Phase 1 after FDA clearance of its investigational new drug application. Enveda plans to use the new financing to carry that program toward mid-stage testing while advancing additional candidates behind it.

Why the Investor Mix Matters

The syndicate reflects the problem Enveda is trying to solve. Healthcare investors can evaluate trial design, regulatory risk, and competitive drug profiles. Technology investors can underwrite the data, automation, and platform dynamics that determine how quickly the pipeline can replenish itself. Enveda needs both arguments to hold at once.

That makes Catalio's leadership and Petrocheilos's board seat especially relevant. The firm invests across private, public, and credit markets in healthcare, while new participants such as ICONIQ and Lightspeed bring experience financing technology companies through major scaling periods. The round is a bet on Enveda as a full-stack drug developer, not merely a software layer sold to pharmaceutical companies.

The Clinical Handoff Becomes the Company

AI drug discovery has attracted capital by promising a broader search space and a faster path to viable candidates. Enveda now has enough clinical programs to face the harder question: whether its discovery advantage produces medicines that remain differentiated as trials become larger, longer, and less forgiving.

The Series E gives Enveda room to build the development organization around that question. It can run later-stage studies, expand indications, deepen the pipeline, and keep feeding PRISM with laboratory evidence. It also raises the cost of being wrong. A platform that generates candidates quickly still has to choose the right trials, manage safety, recruit patients, satisfy regulators, and allocate capital across competing programs.

Enveda's next chapter will be written where machine learning meets clinical operations. The company has already made nature's chemistry more searchable. The $311M now finances the slower work of learning which discoveries can carry the weight of a medicine.